AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22717418 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 7.5 mg (fed)
Number of subjects: 35
Study 22717418 — intervention group
Group type: COMPARATOR
Intervention: IRO 1 × 15 mg (fed)
Number of subjects: 35
Study 22717418 — intervention group
Group type: COMPARATOR
Intervention: IRO‐A and IRO tablets (safety profile)
Number of subjects: 35
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaze (G)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing discs (Sof-Lex) (Sl)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain polishing kit (NTI) (Pk)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain polishing kit (Dialite II) (Di)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond polishing paste (Sparkle) (Sp)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium silicate based cleaning and polishing prophy paste (Zircate) (Zr)
Number of subjects: 55
Study 20379676 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide polishing paste (Prisma Gloss) (Pg)
Number of subjects: 55
Study 20379676 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - no surface treatment
Number of subjects: 55
Study 18053120 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0125 mg/kg/d of GH subcutaneously added to standard therapy
Number of subjects: 24
Study 18053120 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 24
Study 15632819 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist devices
Number of subjects: 129
Study 15632819 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study 11105542 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL (Allergan SI40NB)
Number of subjects: 35
Study 11105542 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (Alcon Acrysof MA60BM)
Number of subjects: 35
Study 11105542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 35
Study 9308144 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated dive to 375 kPa in a hyperbaric chamber
Number of subjects: 8
Study 9308144 — intervention group
Group type: COMPARATOR
Intervention: Control exercise at ambient pressure
Number of subjects: 8
Study 8476802 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 min incremental oxytocin infusion
Number of subjects: 90
Study 8476802 — intervention group
Group type: COMPARATOR
Intervention: 15 min incremental oxytocin infusion
Number of subjects: 90
Study 3774206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 50 mg/day
Number of subjects: 60
Study 3774206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 100 mg/day
Number of subjects: 60
Study 3774206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30304712 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater injection self-efficacy
Number of subjects: 510
Study 30304712 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater length of the relationship
Number of subjects: 510
Study 30304712 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater relationship communication
Number of subjects: 510
Study 27277211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protamine dosing (0.8 protamine-to-heparin ratio; n=49)
Number of subjects: 96
Study 27277211 — intervention group
Group type: COMPARATOR
Intervention: High protamine dosing (1.3 protamine-to-heparin ratio; n=47)
Number of subjects: 96
Study 23196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SPA) with 7.5 mg hyperbaric bupivacaine
Number of subjects: 50
Study 23196892 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) with Propofol and Fentanyl
Number of subjects: 50
Study 21446929 — intervention group
Group type: EXPERIMENTAL
Intervention: ST analysis of the fetal ECG (STAN)
Number of subjects: 566
Study 21446929 — intervention group
Group type: COMPARATOR
Intervention: CTG only
Number of subjects: 566
Study 21446929 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG plus ST analysis
Number of subjects: 566
Study 21446929 — intervention group
Group type: EXPERIMENTAL
Intervention: ST analysis to prevent one case of metabolic acidosis
Number of subjects: 566
Study 18423809 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 203
Study 18423809 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 203
Study 16545254 — intervention group
Group type: EXPERIMENTAL
Intervention: PiKo‐1 device
Number of subjects: 40
Study 14696681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Neiguan (PC-6), Zusanli (ST-36), and Sanyinjiao (SP-6) for 3 minutes, twice a day
Number of subjects: 41
Study 14696681 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure for 3 minutes, twice a day
Number of subjects: 41
Study 11232980 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP-based therapy group (CB Group, CDDP+VDS+tegafur+OK-432 or CDDP+OK-432+mediastinal irradiation)
Number of subjects: 94
Study 11232980 — intervention group
Group type: COMPARATOR
Intervention: Immunochemotherapy group (IC Group, tegafur+OK-432)
Number of subjects: 94
Study 9316524 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TD‐NTG) 0.2 to 0.4 mg/h
Number of subjects: 72
Study 9316524 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TD‐NTG)
Number of subjects: 72
Study 9316524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8468440 — intervention group
Group type: COMPARATOR
Intervention: moclobemide, 450 mg/day
Number of subjects: 12
Study 3545141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole, 200 mg via the gastrointestinal tract daily for 21 days or until one week after discharge from the SICU.
Number of subjects: 57
Study 3545141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 29702246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 43
Study 29702246 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 43
Study 26526926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungisome™ 5 mg/kg daily for 2 days (Group A)
Number of subjects: 120
Study 26526926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungisome™ 7.5 mg/kg daily for 2 days (Group B)
Number of subjects: 120
Study 25436051 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 44
Study 25436051 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 44
Study 22718708 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-enhancing group intervention (4 half-day sessions)
Number of subjects: 566
Study 22718708 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (literature package)
Number of subjects: 566
Study 20009936 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 88
Study 20009936 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 88
Study 18418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Gantang comprehensive therapeutic program (FHGP)
Number of subjects: 142
Study 18418964 — intervention group
Group type: COMPARATOR
Intervention: Conventional TCM and Western medicine therapeutic program
Number of subjects: 142
Study 20544413 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention Program (PIP)
Number of subjects: 115
Study 20544413 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study 16142731 — intervention group
Group type: EXPERIMENTAL
Intervention: Management-focused intervention addressing hazardous substance exposures over 16 months
Number of subjects: 15
Study 16142731 — intervention group
Group type: COMPARATOR
Intervention: Control group (prevalent practice, more downstream, worker-focused)
Number of subjects: 15
Study 12145058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg)
Number of subjects: 52
Study 12145058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 52
Study 9926097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 48
Study 9926097 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural stress management
Number of subjects: 48
Study 9926097 — intervention group
Group type: COMPARATOR
Intervention: No treatment waiting list control group
Number of subjects: 48
Study 9926097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy and Behavioural stress management
Number of subjects: 48
Study 8139083 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks
Number of subjects: 663
Study 8139083 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks
Number of subjects: 663
Study 8139083 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/d of tacrine for the last 12 weeks
Number of subjects: 663
Study 8139083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment
Number of subjects: 663
Study 8139083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 3370062 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 6
Study 3370062 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 6
Study 3370062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 6
Study 29700058 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 750
Study 29700058 — intervention group
Group type: EXPERIMENTAL
Intervention: History of AF
Number of subjects: 750
Study 29700058 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex (after propensity score adjustment)
Number of subjects: 750
Study 29700058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior direct current cardioversion
Number of subjects: 750
Study 29700058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 750
Study 27759930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Cyclical Etidronate Therapy
Number of subjects: 0
Study 24321442 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial KOA group
Number of subjects: 14
Study 24321442 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 22986600 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitor group
Number of subjects: 0
Study 22986600 — intervention group
Group type: COMPARATOR
Intervention: Imaging and clinical examination group
Number of subjects: 0
Study 20732948 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 20732948 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 toddler dose
Number of subjects: 0
Study 20732948 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 18560843 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 926
Study 18560843 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 926
Study 16879437 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5/15 mg once daily
Number of subjects: 716
Study 12947359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg bid)
Number of subjects: 7329
Study 12947359 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to INR 2.0-3.0)
Number of subjects: 7329
Study 10374139 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) including all items
Number of subjects: 105
Study 10374139 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 105
Study 8909936 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g corn peptide
Number of subjects: 20
Study 8909936 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g corn peptide
Number of subjects: 20
Study 8909936 — intervention group
Group type: COMPARATOR
Intervention: Control (no corn peptide)
Number of subjects: 20
Study 1867581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 2 g single dose (Group I)
Number of subjects: 90
Study 1867581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 1 g per day for 3 days (Group II)
Number of subjects: 90
Study 1867581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 1 g per day for 7 days (Group III)
Number of subjects: 90
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 2.5 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 100 mg + Diazepam 5 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 100 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 2.5 mg and 5 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 100 mg + Diazepam 2.5 mg and 5 mg
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 12
Study 6817770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 12
Study 30335131 — intervention group
Group type: EXPERIMENTAL
Intervention: PMCb (paclitaxel plus nonpegylated liposomal doxorubicin plus carboplatin)
Number of subjects: 315
Study 30335131 — intervention group
Group type: COMPARATOR
Intervention: PM (paclitaxel plus nonpegylated liposomal doxorubicin)
Number of subjects: 315
Study 26936333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (low-GI) diet
Number of subjects: 59
Study 26936333 — intervention group
Group type: COMPARATOR
Intervention: High-fiber (HF) diet
Number of subjects: 59
Study 25876339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (needling technique for benefiting qi, promoting blood circulation, regulating mind and improving intelligence)
Number of subjects: 141
Study 25876339 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5 mg tablet once every night for 4 weeks, increased to 10 mg tablet after 4 weeks)
Number of subjects: 141
Study 22901981 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of Labor (IoL)
Number of subjects: 195
Study 22901981 — intervention group
Group type: COMPARATOR
Intervention: Expectant Management (EM)
Number of subjects: 195
Study 19891804 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behaviour therapy (CBT)
Number of subjects: 63
Study 19891804 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 63
Study 18461182 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face masks
Number of subjects: 198
Study 18461182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene
Number of subjects: 198
Study 18461182 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 198
Study 16325036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (statin group)
Number of subjects: 60
Study 16325036 — intervention group
Group type: COMPARATOR
Intervention: Adult Treatment Panel-III diet therapy (diet group)
Number of subjects: 60
Study 15486892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in children with PBM preoperatively
Number of subjects: 12
Study 15486892 — intervention group
Group type: COMPARATOR
Intervention: Serum pancreatic isoamylases in normal controls
Number of subjects: 12
Study 15486892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in pigs preoperatively
Number of subjects: 12
Study 15486892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pancreatic isoamylases in pigs 30 and 60 days after model establishment
Number of subjects: 12
Study 11120421 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 77
Study 11120421 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 77
Study 9401590 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-leg exercise for 30 min at 60% of two-leg VO2 max
Number of subjects: 12
Study 9401590 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg exercise for 30 min at 60% of one-leg VO2 max
Number of subjects: 12
Study 9401590 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg exercise (one-leg TW) at 60% of one-leg VO2 max with total work equal to two-leg trial (duration approximately 50 min)
Number of subjects: 12
Study 9401590 — intervention group
Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 12
Study 8445203 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 0
Study 8445203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3510214 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal metatarsal osteotomy
Number of subjects: 33
Study 3510214 — intervention group
Group type: COMPARATOR
Intervention: Keller's arthroplasty
Number of subjects: 33
Study 30500142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.0%
Number of subjects: 885
Study 30500142 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 885
Study 27250984 — intervention group
Group type: EXPERIMENTAL
Intervention: Live visual and auditory feedback on time under tension using BandCizer™ and an iPad during a 6-week intervention period.
Number of subjects: 40
Study 27250984 — intervention group
Group type: COMPARATOR
Intervention: No feedback on time under tension during a 6-week intervention period.
Number of subjects: 40
Study 24996573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio (plasma, platelets, and red blood cells)
Number of subjects: 680
Study 24996573 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 transfusion ratio (plasma, platelets, and red blood cells)
Number of subjects: 680
Study 21879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) therapy
Number of subjects: 25
Study 21879233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 21879233 — intervention group
Group type: COMPARATOR
Intervention: Both PMR and Control groups
Number of subjects: 25
Study 20509796 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband Imaging TUR (NBI TUR)
Number of subjects: 62
Study 20509796 — intervention group
Group type: COMPARATOR
Intervention: Standard TUR
Number of subjects: 62
Study 17973267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus dexamethasone (Cy-Dex)
Number of subjects: 0
Study 17973267 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and dexamethasone (VAD)
Number of subjects: 0
Study 15999255 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 16
Study 15999255 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 16
Study 15999255 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin solution
Number of subjects: 16
Study 14557446 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide-metformin (flutamide 62.5 mg/d) in OC- teenagers
Number of subjects: 45
Study 14557446 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide-metformin added to gestodene-containing OC in OC+ women
Number of subjects: 45
Study 11783156 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxinsu capsule (SXSC)
Number of subjects: 150
Study 11783156 — intervention group
Group type: COMPARATOR
Intervention: Yixin oral liquid (YXOL)
Number of subjects: 150
Study 11783156 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxinsu capsule (SXSC) and openly treated group (OTG)
Number of subjects: 150
Study 11783156 — intervention group
Group type: COMPARATOR
Intervention: Control group (OTG)
Number of subjects: 150
Study 7878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Common and distinctive stimulus components
Number of subjects: 0
Study 7878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Common stimulus components
Number of subjects: 0
Study 7878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive stimulus components
Number of subjects: 0
Study 2196623 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 0
Study 2196623 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 60 mg/day
Number of subjects: 0
Study 2196623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (various doses)
Number of subjects: 0
Study 354472 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticaine 2% without adrenaline
Number of subjects: 0
Study 354472 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 2% without adrenaline
Number of subjects: 0
Study 28808791 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO (25 mL daily)
Number of subjects: 41
Study 28808791 — intervention group
Group type: COMPARATOR
Intervention: Control (25 mL soybean oil daily)
Number of subjects: 41
Study 28808791 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 41
Study 28808791 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 26571218 — intervention group
Group type: EXPERIMENTAL
Intervention: cUS (experimental group)
Number of subjects: 166
Study 26571218 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (experimental group)
Number of subjects: 166
Study 26571218 — intervention group
Group type: COMPARATOR
Intervention: cUS (control group)
Number of subjects: 166
Study 26571218 — intervention group
Group type: COMPARATOR
Intervention: MRI (control group)
Number of subjects: 166
Study 25218850 — intervention group
Group type: EXPERIMENTAL
Intervention: PIND-ORF
Number of subjects: 38
Study 25218850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22451121 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-jet videoendoscope
Number of subjects: 75
Study 22451121 — intervention group
Group type: COMPARATOR
Intervention: Conventional videoendoscope
Number of subjects: 75